Anthera to explore options after lead drug's trial failure

Anthera Pharmaceuticals

12/03/2018 12:19

March 12 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O 
said on Monday it would evaluate all strategic options after its
lead drug failed in a late-stage trial.
    The company also said it would stop developing the drug,
Sollpura, which aimed to treat improper digestion due to cystic
fibrosis.
    Sollpura failed to meet the main goals of the study in
patients with exocrine pancreatic insufficiency due to cystic
fibrosis, the company said.  urn:newsml:reuters.com:*:nGNXchjsNh

 (Reporting by Mrinalini Krothapalli in Bengaluru; Editing by
Savio D'Souza)
 ((mrinalini.krothapalli@thomsonreuters.com;))